Luitpold Pharmaceuticals sells nasal spray Sprix to Egalet
Executive Summary
Daiichi Sankyo Co. Ltd.'s Luitpold Pharmaceuticals Inc. sold Egalet Corp. its marketed Sprix (ketorolac) nasal spray, indicated for short-term moderate-to-severe pain. Egalet paid $7mm, which is subject to change based on the amount of finished goods inventory. The transaction includes all IP and other related assets and liabilities.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice